



Cancer Smart Nanomedicine

Guest Editors:

Dr. Marina Pinheiro

1. LAQV, REQUIMTE,
Departamento de Ciências
Químicas, Faculdade de
Farmácia, Universidade do Porto,
4050-313 Porto, Portugal
2. CHUP, Centro Hospitalar
Universitário do Porto, 4050-313
Porto, Portugal

Dr. Ammad Ahmad Farooqi

Institute of Biomedical and
Genetic Engineering (IBGE),
Islamabad 54000, Pakistan

Deadline for manuscript
submissions:

closed (9 June 2023)

Message from the Guest Editors

Dear Colleagues,

Nanomedicine is revolutionizing the treatment of cancer. The use of nanoparticles has the potential to modulate cancer cells and contribute to the higher anticancer chemotherapy and immunotherapy efficacy. Nanomedicine can be exploited in biomedicine for applications, including imaging, drug delivery and targeting. This Special Issue, “Cancer Smart Nanomedicine”, published by the journal *Cancers*, seeks contributions assessing state-of-the-art research as well as future developments in the field of the prevention, diagnosis and treatment of cancer using nanomedicine. Topics include, but are not limited to, the use of nanoparticles as drug delivery systems for the prevention, diagnosis and treatment of different cancers, including liposomes, lipid nanoparticles, polymeric and gold nanoparticles, among others. Authors are invited to submit their latest results. Original papers and reviews are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)